This study aimed to examine the most reliable evidence on the relationship between early menopause and the risk of heart failure and atrial fibrillation.
Background: Rivaroxaban is an oral anticoagulant approved in the US for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF).
According to the FDA, analysis of preliminary clinical trial data reveals that patients with permanent Atrial Fibrillation who take antiarrhythmic...
This updated version of The British Menopause Society and Women’s Health Concern recommendations on HRT evaluates the evidence on the role of HRT in managing menopausal symptoms as well as that of alternative therapies. It also reviews the effects of HRT on bone, cardiovascular and cognitive function.
Background: The prevalence of atrial fibrillation is increasing rapidly; however, to date, population-based data are lacking on the attributable cost of illness of atrial fibrillation from a societal perspective, including both...
The CASTLE-AF study �described as �potentially guideline-changing�, has been published in the New England Journal of Medicine. The trial, conducted...
Abbott has announced that the FDA approved the company's Amplatzer Amulet Left Atrial Appendage Occluder to treat people with atrial fibrillation (AFib) who are at risk of ischemic stroke.
This study sought to assess the real-world safety profile of rivaroxaban through a pooled analysis of patients with AF enrolled in the XANTUS (Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation) program worldwide.
Eating several servings of nuts every week may help lower the risk of developing atrial fibrillation, also know as heart flutter, finds research published in the online journal, Heart.
Background: The optimal antithrombotic treatment after percutaneous coronary intervention (PCI) with stenting in patients with atrial fibrillation (AF) is unknown. In the ENGAGE AF-TIMI 48 trial, edoxaban was noninferior to...